Literature DB >> 15472124

Molecular interactions leading to lipoprotein retention and the initiation of atherosclerosis.

Maged F Khalil1, William D Wagner, Ira J Goldberg.   

Abstract

Atherosclerosis is distinguished by the accumulation of lipoprotein lipid within the arterial wall. An ionic interaction of positively charged regions of apolipoprotein (apo) B with matrix proteins, including proteoglycans, collagen, and fibronectin, is thought to initiate this process. Proteoglycans are complex glycoproteins containing highly negatively charged carbohydrate chains. These proteins are abundant in atherosclerosis lesions, and they associate with apoB-containing lipoproteins. Several specific regions of apoB may mediate this process. Other lipoprotein-associated proteins, including apoE and lipases, might also participate in this process. In addition, retention may occur via lipoprotein association with other matrix molecules or as a consequence of intra-arterial lipoprotein aggregation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15472124     DOI: 10.1161/01.ATV.0000147163.54024.70

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  27 in total

Review 1.  Lutein, zeaxanthin and mammalian development: Metabolism, functions and implications for health.

Authors:  Elena Giordano; Loredana Quadro
Journal:  Arch Biochem Biophys       Date:  2018-04-11       Impact factor: 4.013

2.  Contribution of macromolecular structure to the retention of low-density lipoprotein at arterial branch points.

Authors:  Gina P Kwon; Jamie L Schroeder; Marcelo J Amar; Alan T Remaley; Robert S Balaban
Journal:  Circulation       Date:  2008-05-27       Impact factor: 29.690

3.  Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via Toll-like receptor 2.

Authors:  Habib Derbali; Yohan Bossé; Nancy Côté; Philippe Pibarot; Audrey Audet; Andree Pépin; Benoit Arsenault; Christian Couture; Jean-Pierre Després; Patrick Mathieu
Journal:  Am J Pathol       Date:  2010-04-09       Impact factor: 4.307

4.  Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice.

Authors:  Adam E Mullick; Wuxia Fu; Mark J Graham; Richard G Lee; Donna Witchell; Thomas A Bell; Charles P Whipple; Rosanne M Crooke
Journal:  J Lipid Res       Date:  2011-02-22       Impact factor: 5.922

5.  Advanced glycation endproduct changes to Bruch's membrane promotes lipoprotein retention by lipoprotein lipase.

Authors:  Marisol Cano; Natalia Fijalkowski; Naoshi Kondo; Sonny Dike; James Handa
Journal:  Am J Pathol       Date:  2011-06-12       Impact factor: 4.307

Review 6.  A role for proteoglycans in vascular disease.

Authors:  Thomas N Wight
Journal:  Matrix Biol       Date:  2018-02-27       Impact factor: 11.583

7.  Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice.

Authors:  Reeba K Vikramadithyan; Yunying Hu; Hye-Lim Noh; Chien-Ping Liang; Kellie Hallam; Alan R Tall; Ravichandran Ramasamy; Ira J Goldberg
Journal:  J Clin Invest       Date:  2005-08-25       Impact factor: 14.808

8.  Binding to heparin triggers deleterious structural and biochemical changes in human low-density lipoprotein, which are amplified in hyperglycemia.

Authors:  Shobini Jayaraman; Olivia R Chavez; Antonio Pérez; Inka Miñambres; Jose Luis Sánchez-Quesada; Olga Gursky
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2020-04-11       Impact factor: 4.698

Review 9.  Immunological aspects of atherosclerosis.

Authors:  S Garrido-Urbani; M Meguenani; F Montecucco; B A Imhof
Journal:  Semin Immunopathol       Date:  2013-11-09       Impact factor: 9.623

10.  Attachment of beta 2-glycoprotein I to negatively charged liposomes may prevent the release of daughter vesicles from the parent membrane.

Authors:  Jasna Urbanija; Blaz Babnik; Mojca Frank; Nejc Tomsic; Blaz Rozman; Veronika Kralj-Iglic; Ales Iglic
Journal:  Eur Biophys J       Date:  2008-01-10       Impact factor: 1.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.